How a Pill Approved 25 Years Ago Transformed Cancer Treatment

Why It Matters

Gleevec proved that molecularly targeted drugs can deliver dramatic, durable responses, reshaping cancer treatment and spurring a wave of precision medicines while highlighting ongoing challenges around drug pricing and access.

Key Takeaways

• Gleevec (imatinib) approved in 2001 after 72‑day FDA review.
• First targeted therapy for chronic myeloid leukemia, halting abnormal enzyme.
• Trial showed 100% response in high‑dose patients with mild side effects.
• Price dropped from $26k/year to a few hundred dollars as generic.
• Sparked development of over 100 targeted cancer drugs worldwide.

Pulse Analysis

The story of Gleevec began in the early 1990s when oncologist Brian Druker questioned the blunt toxicity of chemotherapy and sought a drug that could directly inhibit the BCR‑ABL enzyme created by the Philadelphia chromosome. Collaborating with Novartis chemist Nicholas Lydon, Druker identified imatinib, a molecule that effectively turned the oncogenic switch off. This scientific breakthrough marked a paradigm shift: instead of indiscriminately killing cells, researchers could now intervene at the molecular root of a specific cancer, laying the groundwork for modern precision oncology.

When the first human trials launched in 1998, they enrolled only patients with chronic myeloid leukemia, a rare but well‑characterized disease. Within six months every participant receiving a high dose experienced tumor regression, and side effects remained modest—an unprecedented outcome that ignited worldwide patient interest. Novartis biostatistician Insa Gathmann compiled striking survival curves that convinced regulators the data were genuine, not an error. The FDA, impressed by the clear benefit and safety profile, granted approval in a record‑fast 72‑day review, cementing Gleevec as the first FDA‑approved targeted cancer therapy.

Gleevec’s legacy extends far beyond its initial indication. Its success demonstrated that a deep molecular understanding could translate into life‑saving drugs, prompting the development of more than a hundred targeted agents across oncology. While the drug’s original $26,000‑annual price sparked debate over affordability, the later introduction of generic imatinib reduced costs to a few hundred dollars, dramatically expanding access. Patients like Mel Mann, once given a three‑year life expectancy, now enjoy decades of health, underscoring how a single breakthrough can reshape treatment standards, patient outcomes, and the economics of cancer care.